ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

PCORI Approves $54.8 Million For Clinical Effectiveness Research

August 1, 2014

In Brief: Armitage Appointed to NCAB; UT Board Approves New Clinical Building for MDACC

May 19, 2000

Montefore Oncology Dept. Writes In Support of Peter Wiernik

November 12, 1993

In Brief: Peter Vogt Names Bristol-Myers Winner; Other Awards: Koop, Weinberg, Wynder, Longmire

March 24, 1989

Clinton Budget Proposes Increase For AIDS, tuberculosis, In FY94

April 23, 1993

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

December 27, 2002